AbbVie has partnered with the PGA Tour and the 2026 Presidents Cup, teeing up the “Birdies for Brain Health” initiative to funnel cash to six patient advocacy organizations.
The agreement makes AbbVie, which reported $3.2 billion in neuroscience sales in the second quarter, the official pharmaceutical sponsor of the PGA Tour, a professional golf organization. This month’s 2026 Presidents Cup, a PGA Tour competition between U.S. and international golfers, marks the start of the alliance.
AbbVie is launching “Birdies for Brain Health” at this month’s event, which is being held close to its home in North Chicago, Illinois. The drugmaker will kick off the campaign with a donation to patient advocacy organizations.
Next year, AbbVie will expand the campaign and make donations for every birdie at PGA Tour Signature Events and the FedExCup Playoffs. A player achieves a “birdie” by completing a hole in one shot under par.
Gary Woodland, one of the U.S. captain’s assistants for the 2026 Presidents Cup, is working with AbbVie on the campaign. Woodland, the 2019 U.S. Open champion, underwent surgery in 2023 to remove a benign brain lesion and revealed a diagnosis of post-traumatic stress disorder this year. AbbVie will work with Woodland to bring the campaign “to life through storytelling and engagement.”
“My experience has shown me how important awareness, support and a strong community can be when someone is facing a health challenge," Woodland said in a statement. “‘Birdies for Brain Health’ gives us a meaningful way to use golf's platform to support organizations advancing science and patient advocacy, while helping people with brain health conditions and their care partners know they are not alone.”
AbbVie will split the donations between the American Migraine Foundation, the National Headache Foundation, Mental Health America, the National Alliance on Mental Illness, The Michael J. Fox Foundation for Parkinson’s Research and the Parkinson’s Foundation.
The patient advocacy groups cover the conditions treated by AbbVie’s neuroscience portfolio. AbbVie’s best-selling neuroscience drug is Vraylar, which is approved in major depressive disorder and bipolar I disorder. The company also markets Botox, Qulipta and Ubrelvy in migraine and Vyalev in Parkinson’s disease. Chronic migraine is one of 12 FDA-approved medical conditions for Botox.
AbbVie’s neuroscience sales increased 20% in the second quarter, with all the abovementioned products achieving double-digit growth. The drugmaker expects to win FDA approval for tavapadon in the third quarter, fueling its belief that it can generate peak Parkinson’s sales of more than $5 billion.